» Articles » PMID: 30813319

Reverse Engineering Cancer: Inferring Transcriptional Gene Signatures from Copy Number Aberrations with ICAro

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2019 Mar 1
PMID 30813319
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

The characterization of a gene product function is a process that involves multiple laboratory techniques in order to silence the gene itself and to understand the resulting cellular phenotype via several omics profiling. When it comes to tumor cells, usually the translation process from in vitro characterization results to human validation is a difficult journey. Here, we present a simple algorithm to extract mRNA signatures from cancer datasets, where a particular gene has been deleted at the genomic level, ICAro. The process is implemented as a two-step workflow. The first one employs several filters in order to select the two patient subsets: the inactivated one, where the target gene is deleted, and the control one, where large genomic rearrangements should be absent. The second step performs a signature extraction via a Differential Expression analysis and a complementary Random Forest approach to provide an additional gene ranking in terms of information loss. We benchmarked the system robustness on a panel of genes frequently deleted in cancers, where we validated the downregulation of target genes and found a correlation with signatures extracted with the L1000 tool, outperforming random sampling for two out of six L1000 classes. Furthermore, we present a use case correlation with a published transcriptomic experiment. In conclusion, deciphering the complex interactions of the tumor environment is a challenge that requires the integration of several experimental techniques in order to create reproducible results. We implemented a tool which could be of use when trying to find mRNA signatures related to a gene loss event to better understand its function or for a gene-loss associated biomarker research.

Citing Articles

Applications of Bioinformatics in Cancer.

Brenner C Cancers (Basel). 2019; 11(11).

PMID: 31652939 PMC: 6893424. DOI: 10.3390/cancers11111630.

References
1.
Lefever S, Anckaert J, Volders P, Luypaert M, Vandesompele J, Mestdagh P . decodeRNA- predicting non-coding RNA functions using guilt-by-association. Database (Oxford). 2017; 2017. PMC: 5502368. DOI: 10.1093/database/bax042. View

2.
Northcott P . Cancer: Keeping it real to kill glioblastoma. Nature. 2017; 547(7663):291-292. DOI: 10.1038/nature23095. View

3.
Mermel C, Schumacher S, Hill B, Meyerson M, Beroukhim R, Getz G . GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12(4):R41. PMC: 3218867. DOI: 10.1186/gb-2011-12-4-r41. View

4.
Comisso E, Scarola M, Rosso M, Piazza S, Marzinotto S, Ciani Y . OCT4 controls mitotic stability and inactivates the RB tumor suppressor pathway to enhance ovarian cancer aggressiveness. Oncogene. 2017; 36(30):4253-4266. DOI: 10.1038/onc.2017.20. View

5.
Boettcher M, McManus M . Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR. Mol Cell. 2015; 58(4):575-85. PMC: 4441801. DOI: 10.1016/j.molcel.2015.04.028. View